Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection,Allergy

当前位置： X-MOL 学术 › Allergy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection
Allergy ( IF 12.6 ) Pub Date : 2021-09-14 , DOI: 10.1111/all.15091
Ismail Cem Yilmaz _{1,

2} , Emre Mert Ipekoglu ₁ , Artun Bulbul ₂ , Nilsu Turay ₂ , Muzaffer Yildirim ₂ , Irem Evcili ₂ , Naz Surucu Yilmaz ₁ , Nese Guvencli ₁ , Yagmur Aydin ₁ , Bilgi Gungor ₂ , Berfu Saraydar ₂ , Asli Gulce Bartan ₂ , Bilgehan Ibibik ₂ , Tugce Bildik ₂ , İlayda Baydemir ₁ , Hatice Asena Sanli ₁ , Basak Kayaoglu ₁ , Yasemin Ceylan ₂ , Tugce Yildirim ₂ , Irem Abras ₂ , Ihsan Cihan Ayanoglu ₁ , Sefa Burak Cam ₃ , Eda Ciftci Dede ₄ , Merve Gizer ₅ , Osman Erganis ₆ , Fahriye Sarac ₇ , Serdar Uzar ₇ , Hakan Enul ₇ , Cumhur Adiay ₇ , Gamze Aykut ₂ , Hivda Polat ₈ , Ismail Selim Yildirim ₈ , Saban Tekin ₈ , Gulay Korukluoglu ₉ , Hasan Ersin Zeytin ₁₀ , Petek Korkusuz ₃ , Ihsan Gursel ₂ , Mayda Gursel ₁

Affiliation

Vaccines that incorporate multiple SARS-CoV-2 antigens can further broaden the breadth of virus-specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS-CoV-2 VLP vaccine that incorporates the four structural proteins of SARS-CoV-2.

中文翻译：